Medical device company C2Dx Inc. has acquired the T/Pump product line from Stryker Corp. Both firms are based in Kalamazoo, which has become a medical technology powerhouse highlighted by the COVID-19 vaccine being produced by Pfizer.
Kalamazoo also is home to multiple medical technology parks, Western Michigan University, and is a large producer of medical devices and various pharmaceuticals.
The T/Pump provides localized temperature therapy for pain relief and patient comfort. It is often used for orthopedic conditions such as acute injuries, chronic pain, and muscle strains, as well as skin trauma, burns, contusions, and other localized pain diagnoses, likes arthritis and neuritis. Controlled warming and cooling temperature settings and multiple treatment cycle options allow therapy to be customized to each patient’s needs.
The T/Pump is the second product line for C2Dx, joining its initial acquisition of the STIC Intra-Compartmental Pressure Monitor.
“Our leadership team has extensive experience leading all phases of medical device manufacturing,” says Kevin McLeod, founder and CEO of C2Dx. “We have proven ourselves with a very successful initial product offering, and now we are excited to offer another valuable product and further pursue C2Dx’s mission.”
C2Dx was founded by McLeod and Plymouth Growth, an Ann Arbor-based growth capital firm. Its stated mission is to grow resources, jobs, and opportunities in west Michigan. To launch its first product, C2Dx brought together previous Stryker executives, each with more than 20 years in leadership.
Stryker offers products and services for orthopaedics, medical and surgical, neurotechnology, and spine applications. In 2019, the company reported $14.9 billion in consolidated net sales. Results for 2020 will be reported shortly.